OBJECTIVE: To assess the effect of vitamin C supplementation on serum uric acid (SUA) by pooling the findings from published randomized controlled trials (RCTs). METHODS: A total of 2,082 publications identified through systematic search were subjected to the following inclusion criteria: 1) RCTs conducted on human subjects, 2) reported end-trial SUA means and variance, 3) study design with oral vitamin C supplementation and concurrent control groups, and 4) trial duration of at least 1 week. Trials that enrolled children or patients receiving dialysis were excluded. Two investigators independently abstracted trial and participant characteristics. SUA effects were pooled by random-effects models and weighted by inverse variance. RESULTS: Thirteen RCTs were identified in the Medline, EMBase, and Cochrane Central Register of Controlled Trials databases. The total number of participants was 556, the median dosage of vitamin C was 500 mg/day, trial size ranged from 8-184 participants, and the median study duration was 30 days. Pretreatment SUA values ranged from 2.9-7.0 mg/dl (Système International d'Unités [SI units]: 172.5-416.4 μmoles/liter). The combined effect of these trials was a significant reduction in SUA of -0.35 mg/dl (95% confidence interval -0.66, -0.03 [P = 0.032]; SI units: -20.8 μmoles/liter). Trial heterogeneity was significant (I(2) = 77%, P < 0.01). Subgroup analyses based on trial characteristics indicated larger reductions in uric acid in trials that were placebo controlled. CONCLUSIONS: In aggregate, vitamin C supplementation significantly lowered SUA. Future trials are needed to determine whether vitamin C supplementation can reduce hyperuricemia or prevent incident and recurrent gout.
OBJECTIVE: To assess the effect of vitamin C supplementation on serum uric acid (SUA) by pooling the findings from published randomized controlled trials (RCTs). METHODS: A total of 2,082 publications identified through systematic search were subjected to the following inclusion criteria: 1) RCTs conducted on human subjects, 2) reported end-trial SUA means and variance, 3) study design with oral vitamin C supplementation and concurrent control groups, and 4) trial duration of at least 1 week. Trials that enrolled children or patients receiving dialysis were excluded. Two investigators independently abstracted trial and participant characteristics. SUA effects were pooled by random-effects models and weighted by inverse variance. RESULTS: Thirteen RCTs were identified in the Medline, EMBase, and Cochrane Central Register of Controlled Trials databases. The total number of participants was 556, the median dosage of vitamin C was 500 mg/day, trial size ranged from 8-184 participants, and the median study duration was 30 days. Pretreatment SUA values ranged from 2.9-7.0 mg/dl (Système International d'Unités [SI units]: 172.5-416.4 μmoles/liter). The combined effect of these trials was a significant reduction in SUA of -0.35 mg/dl (95% confidence interval -0.66, -0.03 [P = 0.032]; SI units: -20.8 μmoles/liter). Trial heterogeneity was significant (I(2) = 77%, P < 0.01). Subgroup analyses based on trial characteristics indicated larger reductions in uric acid in trials that were placebo controlled. CONCLUSIONS: In aggregate, vitamin C supplementation significantly lowered SUA. Future trials are needed to determine whether vitamin C supplementation can reduce hyperuricemia or prevent incident and recurrent gout.
Authors: Howard D Sesso; Julie E Buring; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Robert J Glynn; J Michael Gaziano Journal: JAMA Date: 2008-11-09 Impact factor: 56.272
Authors: Angela Mastaloudis; Jason D Morrow; Dawn W Hopkins; Sridevi Devaraj; Maret G Traber Journal: Free Radic Biol Med Date: 2004-05-15 Impact factor: 7.376
Authors: May A Beydoun; Jose-Atilio Canas; Marie T Fanelli-Kuczmarski; Salman M Tajuddin; Michele K Evans; Alan B Zonderman Journal: Br J Nutr Date: 2017-03-27 Impact factor: 3.718
Authors: Olive Tang; Edgar R Miller; Allan C Gelber; Hyon K Choi; Lawrence J Appel; Stephen P Juraschek Journal: Clin Rheumatol Date: 2017-03-31 Impact factor: 2.980
Authors: Stephen P Juraschek; Allan C Gelber; Hyon K Choi; Lawrence J Appel; Edgar R Miller Journal: Arthritis Rheumatol Date: 2016-12 Impact factor: 10.995
Authors: May A Beydoun; Marie T Fanelli-Kuczmarski; Jose-Atilio Canas; Hind A Beydoun; Michele K Evans; Alan B Zonderman Journal: Br J Nutr Date: 2018-08-31 Impact factor: 3.718